Citations

Clear

3030 citation(s) found for "Susan, M".

The association of physical activity before and after lymphoma diagnosis with survival outcomes
Pophali, Priyanka A. , Ip, Andrew , Flowers, Christopher R. , Link, Brian K. , Farooq, Umar , Allmer, Cristine, Cohen, Jonathon B. , Thompson, Carrie A. , Rosenthal, Allison , Witzig, T.E. , Link, Brian K , Farooq, Umar , Pophali, Priyanka , Larson, Melissa C. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: 1543-1550

10.1002/ajh.25288 | PMID 30230581 Get It

AbstractThe impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) survival was evaluated in a prospective cohort of newly diagnosed lymphoma patients (2002‐2012). We calculated Leisure Score Indexes (mLSI) from the self‐reported usual adult PA (baseline) and at 3‐years post‐diagnosis (FU3), grouping patients by active vs insufficiently active by the American Cancer Society PA guidelines. Associations of PA with survival were assessed using hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype, adjusted for age, sex, baseline BMI, and comorbidity score with change scores further adjusted for baseline PA. Three thousand sixty participants were evaluable at baseline and 1371 at FU3. Active patients had superior survival from baseline [HR (CI): OS 0.82 (0.72‐0.94); LSS 0.74 (0.61‐0.90); EFS 0.92 (0.82‐1.02)] and FU3 [HR (CI): OS 0.64 (0.46‐0.88); LSS 0.32 (0.18‐0.59); EFS 0.82 (0.61‐1.10)] compared to insufficiently active. An increase in mLSI from baseline to FU3 (vs stable mLSI) was associated with superior OS (HR = 0.70, CI 0.49‐1.00) and LSS (HR = 0.49, CI 0.26‐0.94).The continuous change in mLSI at FU3 was significantly associated with OS, LSS and EFS; maintained across subgroups and appeared linear. Higher PA among lymphoma patients at diagnosis and 3 years is significantly associated with OS, LSS, and EFS. Increasing PA after diagnosis is significantly associated with improved OS and LSS supporting an important role for PA in lymphoma survivorship and the need for intervention trials.
Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low‐ and middle‐income countries
Roth, Daniel , Aloia, John F. , Bergeron, Gilles, Brown, Kenneth H. , Calvo, Mona S. , Combs, Gerald F., De‐Regil, Luz Maria , Jones, Kerry S. , Kapner, Hallie, Martineau, Adrian R. , Schleicher, Rosemary L. , Thacher, Tom D. , Whiting, Susan J. , Thacher, Thomas D , Abrams, Steven A. , Bourassa, Megan W. , Cashman, Kevin D. , Jefferds, Maria Elena , Neufeld, Lynnette Marie

Mayo Clinic

Annals of the New York Academy of Sciences | September 18, 2018 | Volume: 1430 | Issue: 1 | Pages: 44-79

10.1111/nyas.13968 | PMID 30225965 Get It

Abstract Vitamin D is an essential nutrient for bone health and may influence the risks of respiratory illness, adverse pregnancy outcomes, and chronic diseases of adulthood. Because many countries have a relatively low supply of foods rich in vitamin D and inadequate exposure to natural ultraviolet B (UVB) radiation from sunlight, an important proportion of the global population is at risk of vitamin D deficiency. There is general agreement that the minimum serum/plasma 25‐hydroxyvitamin D concentration (25(OH)D) that protects against vitamin D deficiency–related bone disease is approximately 30 nmol/L; therefore, this threshold is suitable to define vitamin D deficiency in population surveys. However, efforts to assess the vitamin D status of populations in low‐ and middle‐income countries have been hampered by limited availability of population‐representative 25(OH)D data, particularly among population subgroups most vulnerable to the skeletal and potential extraskeletal consequences of low vitamin D status, namely exclusively breastfed infants, children, adolescents, pregnant and lactating women, and the elderly. In the absence of 25(OH)D data, identification of communities that would benefit from public health interventions to improve vitamin D status may require proxy indicators of the population risk of vitamin D deficiency, such as the prevalence of rickets or metrics of usual UVB exposure. If a high prevalence of vitamin D deficiency is identified (>20% prevalence of 25(OH)D < 30 nmol/L) or the risk for vitamin D deficiency is determined to be high based on proxy indicators (e.g., prevalence of rickets >1%), food fortification and/or targeted vitamin D supplementation policies can be implemented to reduce the burden of vitamin D deficiency–related conditions in vulnerable populations.
Fall Risk and Outcomes Among Patients Hospitalized With Cardiovascular Disease in the Community
Manemann, Sheila M., Chamberlain, Alanna M. , Boyd, Cynthia M. , Miller, Donna , Poe, Kimberly, Weston, Susan A., Koepsell, Ellen E., Jiang, Ruoxiang , Roger, Véronique L. , Poe, Kimberly L, Chamberlain, Alanna M , Miller, Donna M , Cheville, Andrea

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 16, 2018 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.117.004199 | PMID 30354374 Get It

Background As the population with cardiovascular disease ages, geriatric conditions are of increasing relevance. A possible geriatric prognostic indicator may be a fall risk score, which is mandated by The Joint Commission to be measured on all hospitalized patients. The prognostic value of a fall risk score on outcomes after dismissal is not well known. Thus, we aimed to determine whether a fall risk score is associated with death and hospital readmissions in patients with a recent incident cardiovascular disease event. Methods and Results In this retrospective cohort study, Olmsted County, MN patients with incident heart failure, myocardial infarction, or atrial fibrillation between August 1, 2005, and December 31, 2011, who were hospitalized within 180 days after the event were studied. Fall risk was measured by the Hendrich II fall risk model. Patients were followed for death or readmission within 30 days or 1 year. Among 2456 hospitalized patients with recent incident cardiovascular disease (549 heart failure, 784 myocardial infarction, 1123 atrial fibrillation; mean [SD] age, 71 [15] years; 55% men), the fall risk score was high in 22% of patients and moderate in 38%. The risk of death was increased if the fall risk score was increased, independent of age and comorbidities (moderate hazard ratio, 1.51; 95% CI, 1.09–2.08; high hazard ratio, 3.49; 95% CI, 2.52–4.85). Similarly, the risk of 30-day readmissions was substantially increased with a greater fall risk score (moderate hazard ratio, 1.29; 95% CI, 1.03–1.62; high hazard ratio, 1.63; 95% CI, 1.23–2.15). Results were similar for readmissions within 1 year. Conclusions More than half of hospitalized patients with recent incident cardiovascular disease have an elevated fall risk score, which is associated with an increased risk in readmissions and death. These results delineate an approach for risk stratification and management that may prevent readmissions and improve survival.
Reactivation of Chagas disease among heart transplant recipients in the United States, 2012‐2016
Gray, Elizabeth B. , Hoz, Ricardo M. La , Green, Jaime S. , Vikram, Holenarasipur R. , Benedict, Theresa, Rivera, Hilda N., Montgomery, Susan P. , Vikram, Holenarasipur R. , La Hoz, Ricardo M

Mayo Clinic

Transplant Infectious Disease | September 11, 2018 | Volume: 20 | Issue: 6 | Pages: No page available

10.1111/tid.12996 | PMID 30204269 Get It

AbstractBackgroundHeart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non‐endemic countries.MethodsWe present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule.ResultsOf the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow‐up (median: 60 weeks).ConclusionsTransplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.
Association of CD49d expression with small lymphocytic lymphoma (SLL) presentation of chronic lymphocytic leukemia (CLL).
Chaffee, Kari G. , Achenbach, Sara J., Call, Timothy G. , Jelinek, Diane F., Hanson, Curtis A. , Strati, Paolo , Slager, Susan L. , Kay, Neil E. , Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19008-e19008

10.1200/jco.2016.34.15_suppl.e19008 Get It

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011 Get It

First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Lim, Ho Yeong , Kim, Tae‐You, Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Hong, David S. , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan, Kang, Yoon‐Koo

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS2597-TPS2597

10.1200/jco.2016.34.15_suppl.tps2597 Get It

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
Sachdev, Jasgit C. , Ejadi, Samuel, Kim, Tae‐You, Lim, Ho Yeong , Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Beg, Muhammad Shaalan , Hong, David S. , Kang, Yoon‐Koo , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2508-2508

10.1200/jco.2016.34.15_suppl.2508 Get It

Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.
Walsh, Michael F. , Gaddam, Pragna, DiGiovanni, Laura , Dolinsky, Jill S. , Klein, Rachel , Lincoln, Stephen E. , Allen, Brian, Leighton, Justin, Strom, Charles M. , Ranger-Miller, Vanessa, Offit, Kenneth , Balmañà, Judith , Sittler, Taylor , Brown, Kyle, Garber, Judy E. , Couch, Fergus J. , Domchek, Susan M. , Robson, Mark E.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1518-1518

10.1200/jco.2016.34.15_suppl.1518 Get It